title: [The role of the Fanconi anemia pathway in the pathophysiology of ovarian cancer].
abstract: We reviewed the literature on the relationship between the Fanconi anemia pathway (FA) and response to chemotherapy in patients with ovarian cancer. Despite continuous developments in medicine, ovarian cancer remains a challenge for both, physicians and researchers seeking ways to achieve better results of chemotherapy combined with other targeted therapies. Clinically relevant resistance to chemotherapy is a major problem in treating ovarian cancer. Researchers continue to investigate mechanisms responsible for drug resistance in order to develop better therapeutic methods against ovarian cancer. Among the resistance mechanisms, defects in DNA repair, including the FA pathway may be important in increasing the sensitivity of ovarian cancer cells to chemotherapy agents at the clinical level. A growing number of data has shown that disruption of the FA genes may be a useful predictor of OC sensitivity to chemotherapy agents whose activity is based on DNA crosslinking mechanisms.
authors: Agnieszka
authors: A
authors: Synowiec
authors: Jolanta
authors: J
authors: Szenajch
authors: Gabriel
authors: G
authors: Wcisło
authors: Cezary
authors: C
authors: Szczylik
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D004260:DNA Repair; D004261:DNA Replication; D019008:Drug Resistance, Neoplasm; D005199:Fanconi Anemia / Q000209:etiology* / Q000378:metabolism*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D016387:Women's Health
chemical_list: D000970:Antineoplastic Agents